FrancophonIA/ELRC3.0 huggingface dataset:
English: Potential complications can often be avoided by ensuring that patients: - are not sensitive to human normal immunoglobulin by initially injecting the product slowly (at an initial rate of 0.01 ml/kg/min) - are carefully monitored for any symptoms throughout the infusion period.
Croatian: - provjeri da bolesnici nisu osjetljivi na normalni ljudski imunoglobulin, što se ispituje polaganom početnom brzinom injiciranja lijeka (od 0,01/kg/min)
English: PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING VIAL LABEL (5 g, 10 g and 20 g)
Croatian: PODACI KOJI SE MORAJU NALAZITI NA UNUTARNJEM PAKIRANJU NALJEPNICA BOČICE (5 g, 10 g i 20 g)
English: 50 ml, 100 ml or 200 ml solution in a vial (type II glass) with stopper (chloro-butyl-rubber).
Croatian: Staklena bočica (staklo tip II) s 50 ml, 100 ml ili 200 ml otopine s gumenim čepom (klorobutil guma).
English: Again, if tolerated, advance to 0.04 ml/kg/min for the third 30 minutes.
Croatian: Ako se i dalje dobro podnosi, brzinu infuzije potrebno je povisiti na 0,04 ml/kg/min tijekom idućih 30 minuta.
English: Ear and labyrinth disorders Vertigo
Croatian: Poremećaji uha i labirinta vertigo često manje često bol u uhu manje često
English: Flebogamma DIF contains sodium
Croatian: Flebogamma DIF sadrži natrij
English: Primary immune thrombocytopenia
Croatian: Primarna imunotrombocitopenija
English: ● abdominal discomfort and distension
Croatian: ● nelagoda u trbuhu i nadimanje trbuha
English: Grifols Polska Sp. z o. o. Tel: +48 22 378 85 60
Croatian: Tel: +48 22 378 85 60
English: In patients at risk, the use of IVIg products that do not contain these excipients may be considered.
Croatian: Ig terapiju lijekovima koji ne sadržavaju te pomoćne tvari.
English: • pruritus (itching)
Croatian: • astenija (umor)
English: The recommended infusion rate given under section 4.2 must be closely followed.
Croatian: Treba se strogo pridržavati preporučene brzine infuzije kako je navedeno u dijelu 4.2. Zbog moguće pojave simptoma bolesnike se mora pomno pratiti i pažljivo promatrati tijekom cijelog trajanja primjene infuzije.
English: Hepatic impairment
Croatian: Akutno zatajenje bubrega
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Flebogamma DIF 50 mg/ml solution for infusion Human normal immunoglobulin (IVIg)
Croatian: NAZIV LIJEKA I PUT(EVI) PRIMJENE LIJEKA Flebogamma DIF 50 mg/ml otopina za infuziju normalni ljudski imunoglobulin (i.v. Ig) Za intravensku primjenu
English: Feeling jittery, Influenza like illness, Infusion site erythema, Infusion site pain, General physical health deterioration
Croatian: eritem na mjestu infuzije, bol na mjestu infuzije, pogoršanje općeg tjelesnog zdravlja manje često manje često
English: What Flebogamma DIF is used for
Croatian: Za što se koristi Flebogamma DIF
English: MARKETING AUTHORISATION NUMBER(S) EU/1/07/404/001
Croatian: 12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/07/404/001
English: The posology in children and adolescents (2 - 18 years) is not different to that of adults as the posology for each indication is given by body weight and adjusted to the clinical outcome of the above mentioned conditions.
Croatian: Doziranje u djece ne razlikuje se od doziranja u odraslih osoba jer se doza također određuje ovisno o tjelesnoj težini djeteta i kliničkom ishodu gore navedenih stanja i bolesti.
English: ● vertigo
Croatian: ● vjetrovi
English: Vomiting
Croatian: Tromboembolija
English: Blood and lymphatic system disorders
Croatian: Poremećaji krvi i limfnog sustava bicitopenija, leukopenija manje često manje često
English: MARKETING AUTHORISATION NUMBER(S) EU/1/07/404/006
Croatian: 12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/07/404/006
English: Diastolic hypotension, Hypotension
Croatian: Krvožilni poremećaji dijastolička hipotenzija,
English: Flebogamma DIF should be infused intravenously at an initial rate of 0.01 - 0.02 ml/kg/min for the first thirty minutes.
Croatian: Flebogamma DIF za primjenu u venu treba primijeniti u infuziji početnom brzinom od 0,01 - 0,02 ml/kg/min tijekom prvih 30 minuta.
English: Body temperature increased
Croatian: ● vrućica (povišena tjelesna temperatura)
English: ● muscle spasms and muscle tightness
Croatian: ● grčevi u mišićima i ukočenost mišića
English: ● upper-airway cough syndrome
Croatian: ● sindrom kašlja iz gornjih dišnih puteva
English: ● dizziness (motion sickness)
Croatian: ● omaglica (bolest kretanja)
English: Epistaxis, Nasal congestion, Upper-airway cough syndrome, Sinus pain, Dyspnoea
Croatian: prsišta i sredoprsja piskanje često manje često epistaksa, kongestija nosa, sindrom kašlja iz gornjih dišnih puteva, bol u sinusima, dispneja manje često
English: ● pruritus
Croatian: • kašalj
English: STATEMENT OF ACTIVE SUBSTANCE(S) One ml contains 50 mg of human normal immunoglobulin (IVIg) of which at least 97% is IgG.
Croatian: NAVOĐENJE DJELATNE(IH) TVARI Jedan ml lijeka sadrži 50 mg normalnog ljudskog imunoglobulina (i.v. Ig) od čega IgG čini najmanje
English: STATEMENT OF ACTIVE SUBSTANCE(S) One ml contains 100 mg of human normal immunoglobulin (IVIg) of which at least 97% is IgG.
Croatian: NAVOĐENJE DJELATNE(IH) TVARI Jedan ml lijeka sadrži 100 mg normalnog ljudskog imunoglobulina (i.v. Ig) od čega IgG čini najmanje
English: This leaflet was last revised in MM/YYYY
Croatian: DATUM REVIZIJE TEKSTA MM/GGGG
English: Loop diuretics Avoidance of concomitant use of loop diuretics
Croatian: - bilježenje volumena izlučene mokraće - praćenje razine serumskog kreatinina
English: Headache
Croatian: Doza
English: Renal and urinary disorders Urinary retention
Croatian: Poremećaji bubrega i mokraćnog sustava retencija urina manje često rijetko
English: • urinary retention
Croatian: • zadržavanje mokraće
English: Frequency of injections
Croatian: Učestalost davanja injekcija
English: Flebogamma DIF should be infused intravenously at an initial rate of 0.01 ml/kg/min for the first thirty minutes.
Croatian: Flebogamma DIF za primjenu u venu treba primijeniti u infuziji početnom brzinom od 0,01 ml/kg/min tijekom prvih 30 minuta.
English: Bronchitis, Wheezing
Croatian: • grčevi u mišićima
English: • nasopharyngitis
Croatian: • proljev
English: ● urticaria
Croatian: ● malaksalost
English: ● flatulence
Croatian: ● proljev
English: NAME OF THE MEDICINAL PRODUCT Flebogamma DIF 100 mg/ml solution for infusion Human normal immunoglobulin (IVIg)
Croatian: Uputa o lijeku: Informacije za korisnika Flebogamma DIF 100 mg/ml otopina za infuziju normalni ljudski imunoglobulin (i.v. Ig)
English: Diastolic hypertension, Hypertension
Croatian: hipotenzija često često dijastolička hipertenzija,
English: Vital signs (body temperature, blood pressure, heart rate and respiratory rate) should be observed during the infusion of Flebogamma DIF.
Croatian: Za vrijeme infuzije lijeka Flebogamma DIF potrebno je pratiti vitalne znakove (tjelesnu temperaturu,
English: • asthenia (fatigue)
Croatian: ● svrbež (pruritus)
English: Renal impairment
Croatian: Diuretici Henleove petlje
English: Device dislocation
Croatian: Imunomodulacija:
English: • cough
Croatian: • bol
English: Do not use Flebogamma DIF
Croatian: Flebogamma DIF.
English: Maintenance doses: 1 g/kg over 1 - 2 consecutive days every 3 weeks.
Croatian: Doze održavanja: 1 g/kg svaka 3 tjedna, kao jedna doza ili u podijeljenim dozama tijekom 2 dana.
English: ● rash
Croatian: ● osip
English: One ml contains 50 mg of human normal immunoglobulin (IVIg) of which at least 97% is IgG.
Croatian: Jedan ml lijeka sadrži 50 mg normalnog ljudskog imunoglobulina (i.v. Ig) od čega IgG čini najmanje
English: • diabetes
Croatian: • šećernu bolest
English: ● lymphoedema
Croatian: ● limfedem
English: What is Prevymis and what is it used for?
Croatian: Što je Prevymis i za što se koristi?
English: The usual recommended dose by mouth or as an infusion is 480 mg once daily.
Croatian: Uobičajena preporučena doza za primjenu kroz usta ili infuzijom iznosi 480 mg jedanput dnevno.
English: Many people have CMV in their body but it is usually inactive and it does not cause harm.
Croatian: Mnoge osobe imaju CMV u tijelu, ali je on uglavnom neaktivan i nema štetne posljedice.
English: What measures are being taken to ensure the safe and effective use of Prevymis?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Prevymis?
English: Why is Prevymis approved?
Croatian: Zašto je Prevymis odobren?
English: Treatment with Prevymis is started on the day of the transplant or on any day up to 28 days afterwards and it is continued for 100 days after the transplantation; longer treatment may be considered in some patients.
Croatian: Liječenje lijekom Prevymis započinje na dan transplantacije ili bilo kojeg dana do 28 dana nakon transplantacije te se nastavlja 100 dana nakon transplantacije; u nekih bolesnika moguće je dulje liječenje.
English: If ciclosporin (a medicine that prevents rejection of the transplant) is used at the same time, the Prevymis dose is reduced to 240 mg once daily.
Croatian: Ako se istodobno primjenjuje ciklosporin (lijek koji sprječava odbacivanje presatka), doza lijeka Prevymis smanjuje se na 240 mg jedanput dnevno.
English: All patients in this study were CMV seropositive, meaning they had come into contact with the virus before and were likely to be carrying it in an inactive form.
Croatian: Svi bolesnici u tom ispitivanju bili su CMV seropozitivni, što znači da su već bili izloženi virusu te da su ga vjerojatno nosili u neaktivnom obliku.
English: What are the risks associated with Prevymis?
Croatian: Koji su rizici povezani s lijekom Prevymis?
English: Of the patients receiving Prevymis, about 38% (122 out of 325) had signs of CMV becoming active 24 weeks after the stem cell transplant compared with 61% of the patients (103 out of 170) receiving placebo.
Croatian: U otprilike 38 % (122 od 325) bolesnika koji su primali lijek Prevymis uočeni su znakovi aktivacije CMV-a 24 tjedna nakon transplantacije matičnih stanica, u usporedbi sa 61 % (103 od 170) bolesnika koji su primali placebo.
English: This is a summary of the European public assessment report (EPAR) for Prevymis.
Croatian: Ovo je sažetak europskoga javnog izvješća o procjeni (EPAR) za lijek Prevymis.
English: The full EPAR for Prevymis can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Cjeloviti EPAR za lijek Prevymis nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The most common side effects with Prevymis (which may affect up to 1 in 10 people) are nausea (feeling sick), diarrhoea and vomiting.
Croatian: Najčešće nuspojave lijeka Prevymis (koje se mogu javiti u do 1 na 10 osoba) su mučnina (osjećaj slabosti), proljev i povraćanje
English: The summary of the opinion of the Committee for Orphan Medicinal Products for Prevymis can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Croatian: Sažetak mišljenja Odbora za lijekove za rijetke bolesti o lijeku Prevymis možete naći na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
English: For CMV to multiply, its genetic material (DNA) needs to be copied and packaged into protein shells to produce more viruses that can then infect other cells.
Croatian: Da bi se CMV umnožavao, njegov se genetski materijal (DNK) treba kopirati i dobiti proteinski omotač kako bi se proizvelo više virusa koji potom mogu inficirati druge stanice.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Prevymis have been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Prevymis nalaze se u sažetku opisa svojstava i u uputi o lijeku.
English: Terminase is involved in packaging the DNA in the protein shells of the virus.
Croatian: Terminaza je uključena u pakiranje DNK-a u proteinski omotač virusa.
English: The European Medicines Agency therefore decided that Prevymis's benefits are greater than its risks and recommended that it be approved for use in the EU.
Croatian: Stoga je Europska agencija za lijekove odlučila da koristi lijeka Prevymis nadmašuju s njim povezane rizike te je preporučila njegovo odobrenje za primjenu u Europskoj uniji.
English: By blocking the enzyme, the medicine prevents viruses from developing properly, so that CMV cannot multiply and infect other cells.
Croatian: Blokiranjem enzima lijek sprječava pravilan razvoj virusa te se CMV ne može umnožavati i inficirati druge stanice.
English: It is not intended to provide practical advice on how to use Prevymis.
Croatian: Svrha sažetka nije davati praktične savjete o primjeni lijeka Prevymis.
English: Prevymis is available as tablets to be taken by mouth and as a concentrate that is made up into a solution for infusion (drip) into a vein and given over about an hour.
Croatian: Lijek Prevymis dostupan je u obliku tableta koje se uzimaju kroz usta i kao koncentrat od kojeg se priprema otopina za intravensku infuziju (drip) koja se primjenjuje u trajanju od otprilike jednog sata.
English: However, CMV can become active in patients whose immune system is weakened such as those having stem cell transplants.
Croatian: Međutim, CMV može postati aktivan u bolesnika s oslabljenim imunosnim sustavom, kao što su oni koji su podvrgnuti transplantaciji matičnih stanica.
English: The combination of Prevymis and ciclosporin must not be used with dabigatran, atorvastatin, pitavastatin, rosuvastatin and simvastatin.
Croatian: Kombinacija lijeka Prevymis i ciklosporina ne smije se istodobno primjenjivati s dabigatranom, atorvastatinom, pitavastatinom, rosuvastatinom i simvastatinom.
English: Prevymis must not be used together with the medicine pimozide, or ergot medicines such as ergotamine and dihydroergotamine.
Croatian: Lijek Prevymis ne smije se istodobno primjenjivati s pimozidom ni s lijekovima koji sadrže derivate ergota kao što su ergotamin i dihidroergotamin.
English: For more information about treatment with Prevymis, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Više informacija o liječenju lijekom Prevymis pročitajte u uputi o lijeku (također dio EPAR-a) odnosno obratite se svojem liječniku ili ljekarniku.
English: Because the number of patients with CMV disease is low, the disease is considered ‘rare', and Prevymis was designated an ‘orphan medicine' (a medicine used in rare diseases) on 15 April 2011.
Croatian: Budući da je broj bolesnika s bolestima uzrokovanima CMV-om nizak, dotična se bolest smatra „rijetkom” te je Prevymis dobio status „lijeka za liječenje rijetkih i teških bolesti” od 15. travnja 2011. Lijek Prevymis sadržava djelatnu tvar letermovir.
English: Other information about Prevymis
Croatian: Ostale informacije o lijeku Prevymis
English: This is expected to prevent CMV disease in transplant recipients who already have CMV in their body.
Croatian: Očekuje se da će to spriječiti bolesti prouzročene CMV-om u primatelja transplantacije koji već imaju CMV u tijelu.
English: It has few side effects unlike other medicines used for the treatment of CMV disease which can damage bone marrow and affect blood cells.
Croatian: Nuspojave lijeka su rijetke, za razliku od ostalih lijekova koji se primjenjuju u liječenju bolesti prouzročenih CMV-om, koji mogu oštetiti koštanu srž i utjecati na krvne stanice.
English: A main study involving 570 adults found Prevymis was more effective than placebo (a dummy treatment) in preventing CMV infection after allogeneic haematopoietic stem cell transplantation.
Croatian: U glavnom ispitivanju na 570 odraslih osoba lijek Prevymis pokazao se djelotvornijim od placeba (prividno liječenje) u sprječavanju infekcije CMV-om nakon alogene transplantacije krvotvornih matičnih stanica.
English: Letermovir, the active substance in Prevymis, blocks a virus enzyme called ‘terminase'.
Croatian: Letermovir, djelatna tvar lijeka Prevymis, blokira virusni enzim naziva „terminaza”.
English: Doctors should consider official guidance on the use of antiviral medicines when using Prevymis.
Croatian: Prilikom primjene lijeka Prevymis liječnici trebaju uzeti u obzir službene smjernice o primjeni antivirusnih lijekova.
English: For practical information about using Prevymis, patients should read the package leaflet or contact their doctor or pharmacist.
Croatian: Praktične informacije o primjeni lijeka Prevymis bolesnici trebaju pročitati u uputi o lijeku, odnosno obratiti se svojem liječniku ili ljekarniku.
English: What benefits of Prevymis have been shown in studies?
Croatian: Koje su koristi od lijeka Prevymis utvrđene u ispitivanjima?
English: Prevymis can only be obtained with a prescription, and treatment should be started by a doctor experienced in managing patients who have had an allogeneic haematopoietic stem cell transplant.
Croatian: Lijek Prevymis izdaje se samo na recept, a liječenje mora započeti liječnik s iskustvom u liječenju bolesnika koji su podvrgnuti alogenoj transplantaciji krvotvornih matičnih stanica.
English: How does Prevymis work?
Croatian: Kako djeluje Prevymis?
English: Allogeneic haematopoietic stem cell transplantation involves using stem cells from a donor to replace the recipient's bone marrow cells to form new bone marrow that produces healthy blood cells.
Croatian: Alogena transplantacija krvotvornih matičnih stanica uključuje zamjenu stanica koštane srži primatelja matičnim stanicama donora kako bi se formirala nova koštana srž koja proizvodi zdrave krvne stanice.
English: Prevymis is effective in preventing CMV from becoming active and causing disease in adult recipients of a stem cell transplantation to replace the bone marrow.
Croatian: Lijek Prevymis djelotvoran je u sprječavanju aktivacije CMV-a i uzrokovanju bolesti u odraslih primatelja u kojih je provedena transplantacija matičnih stanica kako bi se zamijenila njihova koštana srž.
English: Prevymis is an antiviral medicine used to prevent illness caused by cytomegalovirus (CMV) in adults having an allogeneic haematopoietic stem cell transplant to replace their bone marrow.
Croatian: Prevymis je antivirusni lijek koji se primjenjuje za sprječavanje bolesti uzrokovanih citomegalovirusom (CMV) u odraslih osoba koje su podvrgnute alogenoj transplantaciji krvotvornih matičnih stanica kako bi se zamijenila njihova koštana srž.
English: For the full list of side effects reported with Prevymis, see the package leaflet.
Croatian: Potpuni popis nuspojava zabilježenih prilikom primjene lijeka Prevymis potražite u uputi o lijeku.
English: How is Prevymis used?
Croatian: Kako se Prevymis koristi?
English: Date of first authorisation: 18 September 2015
Croatian: Datum prvog odobrenja: 18. rujna 2015.
English: Tell your doctor if you think you may have another infection.
Croatian: Obavijestite svog liječnika ukoliko mislite da biste mogli imati neku drugu infekciju.
English: This medicine should not be given to children under 18 years old because there is not enough information on use in this age group.
Croatian: Ovaj lijek se ne smije davati djeci mlađoj od 18 godina jer nema dovoljno informacija o njegovoj primjeni u ovoj dobnoj skupini.
English: Your doctor may also want to test your blood to make sure you receive an appropriate dose, especially if you have to take this medicine for a long time.
Croatian: Liječnik će Vam također možda htjeti napraviti krvne pretrage kako bi bio siguran da primate odgovarajuću dozu, osobito ako morate uzimati ovaj lijek tijekom dugog razdoblja.
English: Your doctor will decide on the dose that you need.
Croatian: Liječnik će odrediti koja Vam je doza potrebna.
English: *CrCL estimated using Cockcroft-Gault formula.
Croatian: *CrCl procijenjen pomoću Cockcroft-Gaultove formule.
English: Minimum Inhibitory Concentrations (mg/L)
Croatian: Minimalna inhibitorna koncentracija (mg/l)
English: 15 to 29
Croatian: 15 do 29
English: CrCL (mL/min)*
Croatian: Procijenjeni CrCl (ml/min)*
English: This leaflet was last revised in {month YYYY}.
Croatian: Ova uputa je zadnji puta revidirana u {mjesec GGGG}.
English: Safety and efficacy in paediatric patients have not been established.
Croatian: Sigurnost i djelotvornost u pedijatrijskih bolesnika nisu ustanovljene.
English: 7 days
Croatian: 7 dana
English: CAUTION: THE RECONSTITUTED SOLUTION IS NOT FOR DIRECT INJECTION.
Croatian: OPREZ: REKONSTITUIRANA OTOPINA NIJE NAMIJENJENA ZA IZRAVNU PRIMJENU INJEKCIJE.
English: Tazobactam is a substrate for OAT1 and OAT3.
Croatian: Tazobaktam je supstrat za OAT1 i OAT3.
English: Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Croatian: Potrebno je uzeti u obzir službene smjernice o odgovarajućoj primjeni antibakterijskih lijekova.
English: The final volume is approximately 11.4 mL per vial.
Croatian: Konačni volumen iznosi približno 11,4 ml po bočici.
English: What Zerbaxa is and what it is used for
Croatian: Što je Zerbaxa i za što se koristi
English: 63963, Clermont Ferrand Cedex 9 France
Croatian: 63963, Clermont Ferrand Cedex 9 Francuska
English: Zerbaxa is indicated for the treatment of the following infections in adults (see section 5.1):
Croatian: Zerbaxa je indicirana za liječenje sljedećih infekcija u odraslih (vidjeti dio 5.1):
English: 30 to 50
Croatian: 30 do 50
English: Zerbaxa should only be used during pregnancy if the expected benefit outweighs the possible risks to the pregnant woman and foetus.
Croatian: Zerbaxa se smije primjenjivati tijekom trudnoće samo ako je očekivana korist veća od mogućih rizika za trudnicu i fetus.
English: If super infection occurs during or following treatment, appropriate measures should be taken.
Croatian: Ako tijekom ili nakon liječenja nastupi superinfekcija, potrebno je poduzeti odgovarajuće mjere.
English: White to yellowish powder.
Croatian: Bijeli do žućkasti prašak.
English: **All doses of Zerbaxa are administered intravenously over 1 hour and are recommended for all indications.
Croatian: **Sve doze lijeka Zerbaxa primjenjuju se intravenski tijekom 1 sata i preporučene su za sve indikacije.
English: The medicinal product is photosensitive and should be protected from light when not stored in the original carton.
Croatian: Lijek je fotosenzitivan i potrebno ga je zaštititi od svjetlosti kad se ne čuva u originalnom pakiranju.
English: Treatment with Zerbaxa normally lasts between 4 and 14 days, depending on the severity and location of the infection and on how your body responds to the treatment.
Croatian: Liječenje lijekom Zerbaxa obično traje između 4 i 14 dana, ovisno o težini i mjestu infekcije te o tome kako Vaše tijelo odgovara na liječenje.
English: The safety and efficacy of ceftolozane/tazobactam in children and adolescents below 18 years of age have not yet been established.
Croatian: Sigurnost i djelotvornost ceftolozana/tazobaktama u djece i adolescenata mlađih od 18 godina nisu još ustanovljene.
English: The dose depends on the type of infection that you have, where the infection is in your body and how serious the infection is.
Croatian: Doza ovisi o vrsti infekcije koju imate, mjestu infekcije i stupnju ozbiljnosti infekcije.
English: Non-susceptible micro-organisms
Croatian: Neosjetljivi mikroorganizmi
English: This can increase the time it takes for tazobactam to leave your body.
Croatian: To može produljiti vrijeme koje je tazobaktamu potrebno da se izluči iz tijela.
English: These include: - Probenecid (a medicine for gout).
Croatian: To uključuje: - probenecid (lijek protiv gihta).
English: After reconstitution, chemical and physical in-use stability has been demonstrated for 4 days at 2 to 8°C.
Croatian: Nakon rekonstitucije, dokazana je kemijska i fizikalna stabilnost lijeka u primjeni tijekom 4 dana na temperaturi od 2 do 8°C.
English: Mechanisms of resistance
Croatian: Mehanizmi rezistencije
English: The duration of treatment should follow the recommendations in Table 1.
Croatian: Trajanje liječenja treba odrediti pridržavajući se preporuka iz tablice 1.